Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: IGC announces issuance of second patent for the treatment of Alzheimer’s Using THC
Sep 16, 2022: Quince Therapeutics presents preclinical data at MHSRS 2022 demonstrating preclinical efficacy of bone-targeting platform for traumatic bone injury
Sep 12, 2022: Quince Therapeutics presents preclinical data at ASBMR 2022 demonstrating application of bone-targeting platform for spil fusion and bone cancer indications
Aug 30, 2022: Quince Therapeutics presents preclinical data at OI 2022 demonstrating potential of a targeted abolic for accelerated bone healing of osteogenesis imperfecta fractures
Jul 18, 2022: Alzamend Neuro receives positive pre-IND response from FDA for AL001 treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder
Jun 03, 2022: Innovative hearing restoration trial launches at the Medical College of Wisconsin
May 17, 2022: Alzamend Neuro announces pre-IND submission for AL001 as a treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder
May 05, 2022: Alzamend Neuro announces initiation of phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer’s
Apr 11, 2022: Alzamend Neuro contracts with Altasciences and iResearch Atlanta to mage and conduct its phase IIA study in patients with Alzheimer’s
Mar 28, 2022: Actuate Therapeutics announces poster presentations at the 2022 AACR Annual Meeting
Mar 28, 2022: Alzamend Neuro announces full data set from phase 1 first-in-human clinical trial for AL001 treatment of Dementia Related to Alzheimer’s
Mar 11, 2022: ENTA conducting clinical trial of investigatiol regenerative medication to restore hearing function in sensorineural hearing loss (SNHL) patients
Mar 01, 2022: Actuate Therapeutics announces first patient enrolled in Phase 2 clinical trial of elraglusib plus retifanlimab as investigatiol first line therapy for patients with advanced pancreatic cancer
Feb 07, 2022: Actuate Therapeutics announces initiation of a multicenter randomized trial of elraglusib plus FOLFIRINOX as first line therapy for advanced pancreatic cancer
Dec 22, 2021: AMO Pharma announces expansion of pivotal REACH-CDM study in congenital myotonic dystrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022